Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.12771 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation.
J Hematol Oncol
November 2024
Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, HRC 5860, Milwaukee, WI, 53226, USA.
Article Synopsis
- Mitochondrial DNA (mtDNA) variants in donors significantly affect outcomes for MDS patients following allogeneic hematopoietic cell transplantation (allo-HCT), enhancing prognostic prediction.
- Whole-genome sequencing of 494 donors revealed 1,825 mtDNA variants, with specific variants linked to posttransplant survival and relapse rates.
- Incorporating donor mtDNA genotype, age, and HLA-matching into existing scoring systems can optimize donor selection, potentially improving transplant outcomes for MDS patients.
SARS-CoV-2-Specific T-Cell as a Potent Therapeutic Strategy against Immune Evasion of Emerging COVID-19 Variants.
Int J Mol Sci
September 2024
Institute for Translational Research and Molecular Imaging, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Article Synopsis
- * Researchers investigated using virus-specific T cells (VSTs) from donors to enhance immune responses against SARS-CoV-2 infections.
- * Findings show that these VSTs effectively target multiple viral antigens, maintaining strong cytotoxic effects against both original and variant strains, suggesting their potential for future therapies.
Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model.
iScience
February 2024
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Article Synopsis
- The study addresses a key challenge in treating solid tumors with CAR T cells, specifically the negative effects of the tumor microenvironment (TME).
- Researchers created a modified CAR T cell (G36-PDL1) that not only targets a protein associated with tumors (carbonic anhydrase IX or CAIX) but also secretes an antibody to counteract immune suppression.
- In tests using a mouse model of kidney cancer, the G36-PDL1 CAR T cells showed strong anti-tumor effects by enhancing immune responses and reducing suppressive cells in the TME compared to standard CAR T cells.
Correlative factors of ocular surface lesions after allogeneic hematopoietic stem cell transplantation: A retrospective study.
Front Oncol
November 2022
Department of Ophthalmology, First Affiliated Hospital of Soochow University, Suzhou, China.
Background: Ocular graft-versus-host disease (oGVHD) is one of the complications after allogeneic hematopoietic stem cell transplantation (HSCT), which impairs the quality of life and may indicate poor prognosis. In this retrospective study, the aim was to investigate the characteristics of ocular surface after HSCT, and analyze the risk factors related to the severity of ocular surface lesions.
Methods: 248 post-HSCT patients were enrolled in this retrospective study.
Case report: Rare persistent complete donor chimerism and GVHD following micro-transplantation from HLA haplotype homozygous donors.
Front Immunol
October 2022
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
HLA-mismatched hematopoietic stem cell micro-transplantation (MST) is an effective treatment for older patients (≥60 years) with acute myeloid leukemia. Donor selection for MST is broad, ranging from HLA fully mismatched unrelated donors to HLA partially matched related donors. However, the influence of HLA haplotype homozygous donors such donors on MST has not been studied.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!